Liquid biopsy is a minimally invasive technology for detection of molecular biomarkers. It is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a disease or a tumour through a simple blood sample.Learn More
Similar to the normal cells, even the tumor cells also undergo apoptosis (programmed cell death). These dead tumor cells are engulfed by phagocytes that process the tumour cell DNA which gets released into the blood stream. Thus the name tumour cell free DNA (cfDNA) or circulating tumour DNA (ctDNA). This cfDNA can be analysed for the same genetic aberrations found in tumours, including mutation, amplification, chromosomal rearrangement and hypermethylation.
Direct tissue biopsies are limited in utility by several problems, including the difficulty in acquiring adequate amounts of tissue; limited repeatability, and biases that result from sampling a small area of a single tumor,including those due to tissue heterogeneity.Obtaining biopsies can also be hampered by patient comorbidities and lack of patient compliance. Sampling of a single tumour may not capture all the mutations present.
Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve are few of the many possibilities that has emerged from Liquid Biopsy.
OncoTrack from MedGenome has been developed and validated In INDIA to detect cancer causing DNA from the patients' blood sample. Using NGS technology OncoTrack has an extremely high sensitivity and ability to detect extremely low frequency mutations.Learn More
ONCOTRACK screens for the presence of oncogenic driver mutations in four key genes: EGFR, KRAS, NRAS and BRAF, that has a potential role in clinical decision making. This assay also screens for resistance mutations that demonstrate the mechanism of acquired secondary/primary resistance to these drugs.
In about 10% of patients, wherein the tissue biopsy could not be performed, liquid biopsy could be an alternative, with informed decisions from the patient and the clinician on the false negative/false positivity associated with the assay
Eg. Adenocarcinoma of Lung patient on TKIs
+91 (0)80 67154900 / 67154901